NEWAMSTERDAM PHARMA COMPANY (NAMSW) — Institutional Holders & Hedge Fund Ownership
NEWAMSTERDAM PHARMA COMPANY (NAMSW) institutional ownership: 2 hedge funds and institutional investors, holding 593K shares ($11.9M), as of Q1 2026, per SEC Form 13F-HR filings.
NEWAMSTERDAM PHARMA COMPANY (NAMSW) institutional ownership tracks hedge funds, family offices, and asset managers that disclose 13F positions in NAMSW each quarter. The data covers every 13F filer that disclosed a NAMSW position — top holders by portfolio weight, biggest quarterly buyers and sellers, and positioning shifts.
The top NAMSW shareholders by portfolio weight are Frazier Life Sciences (0.26%) and Deerfield (0.02%).
Top 2 Institutional Holders of NEWAMSTERDAM PHARMA COMPANY (NAMSW) — Q1 2026
| # | Fund | Shares | Market Value | Portfolio Weight |
|---|---|---|---|---|
| 1 | Frazier Life Sciences | 500,333 | $10.0M | 0.26% |
| 2 | Deerfield | 92,787 | $1.9M | 0.02% |
- 2Hedge funds holding
- 593,120Shares held (disclosed)
- $11.9M13F market value
- 0.14%Median portfolio weight
Ownership History
Quarter-by-quarter share count, market value, and portfolio conviction weight (up to 5 of the heaviest weight-by-portfolio funds) of NAMSW. Sourced from 13F filings; reflects long equity positions only.
All Institutional HoldersSortable · searchable
All institutional investors (Max 50) holding NAMSW in the selected quarter. Click a fund name to drill into its full 13F portfolio.
| 1 | Frazier Life Sciences | 500,333 | $10.0M | 0.26% |
| 2 | Deerfield | 92,787 | $1.9M | 0.02% |
Methodology & FAQ
Methodology: How We Track NAMSW Institutional Holdings
Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).
- Who Must File (Reporting Threshold): This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
- What is Included (Data Scope): We capture long positions in Section 13(f) securities for NEWAMSTERDAM PHARMA COMPANY (NAMSW). By SEC regulation, 13F filings do not require the disclosure of short positions, non-U.S. holdings, or OTC derivatives. Listed options are excluded from portfolio weight calculations to ensure comparability across filers.
- Portfolio Weight Explained (Metric Definition): “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to NAMSW on the specific reporting date.
- How to Use This Data (Interpretation): Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
How do you measure hedge fund conviction and institutional concentration in NAMSW?
We evaluate fund conviction by looking at portfolio weight rather than just absolute share count. By tracking how the largest holders —such as Frazier Life Sciences and Deerfield as of Q1 2026— change their position sizing quarter-over-quarter, we help investors distinguish between deliberate position sizing changes and passive mark-to-market drift.
Does the NAMSW ownership data include short interest or options?
SEC Form 13F mandates the disclosure of long positions in Section 13(f) securities, which includes equities and listed options (put and call contracts), but excludes short interest, swaps, and OTC derivatives by regulatory design. On this platform, listed options are excluded from portfolio weight calculations to ensure comparability across filers.
Are family offices and university endowments included in this NAMSW data?
Yes. In addition to traditional hedge funds and large asset managers, any institutional entity exercising investment discretion over at least $100 million in Section 13(f) securities must file a Form 13F. This explicitly includes single-family offices and university endowments. If a qualifying family office or endowment holds NAMSW stock, their allocation is systematically aggregated alongside traditional fund data.
When is the institutional ownership data updated, and is there a reporting lag?
Institutional investment managers are required to file their Form 13F within 45 days after the end of a calendar quarter (the standard “T+45” window). Our platform re-ingests new filings from the SEC EDGAR database on a nightly cycle, typically within 24–48 hours of publication, providing a point-in-time snapshot of reported consensus positioning for NAMSW as of each filing date.